These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 35247393)

  • 21. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
    Shapiro S; Pollock DM; Gillies H; Henig N; Allard M; Blair C; Anglen C; Kohan DE
    Am J Cardiol; 2012 Nov; 110(9):1373-7. PubMed ID: 22858181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials.
    Chin KM; Bartolome S; Miller K; Blair C; Gillies H; Torres F
    Int J Clin Pract; 2014 May; 68(5):568-77. PubMed ID: 24499136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
    Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
    Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 26. Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension.
    Weatherald J; Huertas A; Boucly A; Guignabert C; Taniguchi Y; Adir Y; Jevnikar M; Savale L; Jaïs X; Peng M; Simonneau G; Montani D; Humbert M; Sitbon O
    Chest; 2018 Oct; 154(4):872-881. PubMed ID: 29800550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
    Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
    Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials.
    Blette BS; Moutchia J; Al-Naamani N; Ventetuolo CE; Cheng C; Appleby D; Urbanowicz RJ; Fritz J; Mazurek JA; Li F; Kawut SM; Harhay MO
    Lancet Respir Med; 2023 Oct; 11(10):873-882. PubMed ID: 37230098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials.
    Rose JA; Cleveland JM; Rao Y; Minai OA; Tonelli AR
    Chest; 2016 May; 149(5):1234-44. PubMed ID: 26836910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methamphetamine-associated pulmonary arterial hypertension: data from the national biological sample and data repository for pulmonary arterial hypertension (PAH Biobank).
    Charoenpong P; Dhillon N; Murnane K; Goeders N; Hall N; Keller C; Bhuiyan MAN; Walter R
    BMJ Open Respir Res; 2023 Dec; 10(1):. PubMed ID: 38061804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy.
    Kearney K; Brown K; Celermajer DS; Collins N; Cordina R; Corrigan C; Dwyer N; Feenstra J; Keating D; Keogh A; Kotlyar E; Lavender M; McWilliams T; Williams T; Whitford H; Weintraub R; Wrobel J; Ellender C; Anderson J; Lau EM;
    Chest; 2024 Apr; 165(4):967-977. PubMed ID: 37951349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE).
    Howard LS; Rosenkranz S; Frantz RP; Hemnes AR; Pfister T; Hsu Schmitz SF; Skåra H; Humbert M; Preston IR
    Chest; 2023 Feb; 163(2):407-418. PubMed ID: 36089068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
    Oudiz RJ; Brundage BH; Galiè N; Ghofrani HA; Simonneau G; Botros FT; Chan M; Beardsworth A; Barst RJ;
    J Am Coll Cardiol; 2012 Aug; 60(8):768-74. PubMed ID: 22818063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.
    Kylhammar D; Persson L; Hesselstrand R; Rådegran G
    Scand Cardiovasc J; 2014 Aug; 48(4):223-33. PubMed ID: 24912571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis.
    Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G
    Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
    Frantz RP; McDevitt S; Walker S
    J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.
    Barst RJ; Chung L; Zamanian RT; Turner M; McGoon MD
    Chest; 2013 Jul; 144(1):160-168. PubMed ID: 23429998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.